Table 3.
COVID-19–related research emergent topics.
| Emergent topic groups | Records | 1949–2019 | 2020 (through July 1) |
|---|---|---|---|
| Patient care teaming | 1464 | 3.3% | 2.9% |
| Intensive care unit | 1414 | 1.6% | 3.9% |
| Personal protective equipment | 1409 | 2.2% | 3.5% |
| Symptoms (e.g., fever) | 1364 | 2.2% | 3.3% |
| Computed tomography | 984 | 0.7% | 2.9% |
| C-reactive protein (e.g., d-dimer) | 820 | 1.1% | 2.5% |
| Angiotensin-converting enzyme 2 | 950 | 1.3% | 2.0% |
| Diabetes | 797 | 0.4% | 2.5% |
| Hydroxycholoroquine | 736 | 0.2% | 2.4% |
| Surveys and questionnaires (health knowledge, attitudes, practice) | 663 | 1.8% | 1.2% |
| Cancer | 630 | 0.4% | 1.9% |
| EMBASE | 628 | 0.4% | 1.9% |
| Mental health | 535 | 0.3% | 1.7% |
| Study protocol (e.g., randomization) | 532 | 0.9% | 1.2% |
| Healthcare disparities (inequities) | 492 | 0.2% | 1.5% |
| Surgery | 357 | 0.1% | 1.2% |
| Anticoagulants (thrombosis) | 352 | 0.1% | 1.1% |
| Ritonavir/lopinavir | 319 | 0.2% | 1.0% |
| Infectious disease transmission, vertical (pregnancy) | 308 | 0.5% | 0.8% |
| T cells | 304 | 1.3% | 0.2% |
| Antibodies (IgM, IgG) | 303 | 1.0% | 0.4% |
| Arrhythmias | 259 | 0.1% | 0.8% |
| Education, medical | 220 | 0.1% | 0.7% |
| Olfactory disorders (anosmia) | 212 | 0.0% | 0.7% |
| Neurological manifestations | 212 | 0.2% | 0.6% |
| Molecular docking | 183 | 0.3% | 0.4% |
| Head and neck neoplasms | 176 | 0.1% | 0.6% |
| Orthopedics | 148 | 0.0% | 0.5% |
| Ophthalmology | 112 | 0.0% | 0.4% |